NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives $47.00 Consensus Target Price from Brokerages

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) have earned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $47.00.

NAMS has been the subject of a number of research analyst reports. Leerink Partners restated an “outperform” rating and set a $55.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, January 6th. HC Wainwright began coverage on NewAmsterdam Pharma in a research note on Monday, October 20th. They issued a “buy” rating and a $52.00 price objective for the company. Citigroup lifted their target price on shares of NewAmsterdam Pharma from $42.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Needham & Company LLC upped their target price on NewAmsterdam Pharma from $40.00 to $46.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Finally, Stifel Nicolaus upped their price objective on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th.

NewAmsterdam Pharma Stock Performance

Shares of NASDAQ NAMS opened at $32.99 on Friday. NewAmsterdam Pharma has a fifty-two week low of $14.06 and a fifty-two week high of $42.00. The company has a market cap of $3.74 billion, a PE ratio of -16.09 and a beta of 0.06. The business has a 50-day simple moving average of $34.75 and a two-hundred day simple moving average of $31.60.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its earnings results on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%.The firm had revenue of $0.35 million for the quarter, compared to analyst estimates of $4.54 million. On average, sell-side analysts predict that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Insider Activity at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 32,612 shares of the business’s stock in a transaction on Wednesday, January 28th. The shares were sold at an average price of $31.80, for a total value of $1,037,061.60. Following the completion of the sale, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at $774,425.40. The trade was a 57.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Johannes Jacob Piete Kastelein sold 6,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $33.25, for a total value of $199,500.00. Following the completion of the transaction, the insider owned 73,481 shares in the company, valued at $2,443,243.25. This trade represents a 7.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 298,647 shares of company stock valued at $10,236,050. 20.84% of the stock is owned by company insiders.

Institutional Trading of NewAmsterdam Pharma

A number of hedge funds have recently bought and sold shares of NAMS. Capital World Investors increased its holdings in shares of NewAmsterdam Pharma by 17.1% during the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock worth $279,358,000 after buying an additional 1,434,986 shares during the last quarter. Jennison Associates LLC boosted its stake in NewAmsterdam Pharma by 42.5% in the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock valued at $119,407,000 after acquiring an additional 1,252,451 shares during the period. Duquesne Family Office LLC lifted its position in NewAmsterdam Pharma by 131.2% in the 3rd quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock valued at $54,710,000 after purchasing an additional 1,091,525 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in shares of NewAmsterdam Pharma by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after purchasing an additional 1,062,359 shares during the period. Finally, Maverick Capital Ltd. lifted its position in NewAmsterdam Pharma by 178.8% in the second quarter. Maverick Capital Ltd. now owns 1,531,874 shares of the company’s stock worth $27,742,000 after purchasing an additional 982,405 shares during the period. Institutional investors and hedge funds own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical?stage biopharmaceutical company focused on discovering and developing novel small?molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small?molecule candidates at various stages of preclinical and clinical evaluation.